Table 3.
Number, level and volume of other Modic changes (MC) than the primary Modic changea at baseline and follow-up and the change in the volume according to treatment group
| Volume of other than the primary Modic changea | Mean (SD) | Mean (SD) change | Unadjusted analyses | |||
|---|---|---|---|---|---|---|
| ZA | Placebo | ZA | Placebo | Difference (95% CI) | Pb | |
| Multiple MCs, n (%) | ||||||
| At two levels | 9 (60) | 6 (75) | ||||
| At three levels | 6 (40) | 2 (25) | ||||
| Level of the other than the primary MC, n (%) | ||||||
| L1/2 | 1 (6.7) | 0 (0.0) | ||||
| L2/3 | 1 (6.7) | 1 (12.5) | ||||
| L3/4 | 2 (13.3) | 0 (0.0) | ||||
| L4/5 | 5 (33.3) | 4 (50.0) | ||||
| L5/S1 | 6 (40.0) | 3 (37.5) | ||||
| Volume of M1a (cm3) | ||||||
| Baseline | 0.80 (1.92) | 1.20 (1.62) | ||||
| Follow-up | 1.69 (2.50) | 2.22 (2.20) | 0.89 (2.23) | 1.03 (2.21) | −0.14 (−2.16, 1.89) | 0.89 |
| Volume of M2a (cm3) | ||||||
| Baseline | 6.98 (8.01) | 4.36 (5.27) | ||||
| Follow-up | 6.49 (6.74) | 3.93 (4.72) | −0.49 (2.54) | −0.43 (1.49) | −0.06 (−2.10, 1.98) | 0.95 |
| Total volumea (cm3) | ||||||
| Baseline | 7.78 (8.49) | 5.55 (5.36) | ||||
| Follow-up | 8.18 (7.75) | 6.15 (5.24) | 0.40 (1.09) | 0.60 (1.53) | −0.19 (−1.33, 0.95) | 0.73 |
SD standard deviation, CI confidence interval, ZA zoledronic acid
aThe primary Modic change was assumed to cause patients’ symptoms at baseline
bIndependent samples t-test for change in the volume between the treatment groups